MEDITRANS – An Integrated Project Focusing on Targeted Nanomedicines Concluding Remarks
As mentioned above, one of the main objectives of the MEDITRANS project is to advance selected nanomedicine formulations towards industrial exploitation and clinical application. To realise this ‘bench to clinic’ objective, four targeted nanomedicine systems have been selected on the basis of pre-clinical behaviour criteria for detailed investigation of toxicological and industrial exploitation aspects (the latter related to their suitability for development into a marketable product, e.g. long-term stability, and design of an up-scalable process for large-scale manufacturing). With its integrated ‘bench to clinic’ approach, realised within a structural collaboration between industry and academia, MEDITRANS is well on its way in its mission to promote the progression of targeted nanomedicines towards clinical application. n
1.
Kostarelos K, Lacerda L, Pastorin G, et al., Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type, Nat Nanotechnol, 2007;2:108–13.
2. 3. 4.
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J Control Release, 2000;65:271–84.
Lammers T, Hennink WE, Storm G, Tumour-targeted nanomedicines: principles and practice, Br J Cancer, 2008;99:392–7.
Metselaar JM, Wauben MH, Wagenaar-Hilbers JP, Boerman OC, Storm G, Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating
7.
Gert Storm is a Professor at the Utrecht Institute for Pharmaceutical Sciences. In 2000, he was appointed Chair of Drug Targeting at Utrecht University. In addition to this, in 1999, he was appointed Adjunct Professor at the Royal School of Pharmacy, Copenhagen, and since July 2009 has been an Honorary Professor of Biomacromolecular Drug Delivery at the University of Copenhagen. In 1990–1991 he was senior research scientist at Pharma Bio-Research Consultancy B.V. During this period, he contributed to the design, co-ordination and evaluation of clinical pharmacological studies. In 1988–1989 he was a Visiting Scientist at Liposome Technology Inc. in Menlo Park, US, and a Visiting Assistant Professor at the School of Pharmacy at the University of California San Francisco (UCSF). He is the author or co-author of more than 300 original articles, reviews and book chapters in the field of advanced drug delivery/drug targeting (in particular with liposomal systems), and theme (co-)editor of Advanced Drug Delivery Reviews and the book Long Circulating Liposomes. Old Drugs, New Therapeutics. Professor Storm studied biology at Utrecht University and obtained his PhD in 1987 from the Department of Pharmaceutics at the same university.
liposomes, Arthritis Rheum, 2003;48:2059–66. 5.
Rijcken CJ, Snel CJ, Schiffelers RM, et al., Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies, Biomaterials, 2007;28:5581–93.
6.
Talelli M, Rijcken CJ, Lammers T, et al., Superparamagnetic iron oxide nanoparticles encapsulated in biodegradable thermosensitive polymeric micelles: toward a targeted nanomedicine suitable for image-guided drug delivery, Langmuir, 2009;25:2060–67.
Banciu M, Fens MH, Storm G, Schiffelers RM, Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice, J Control
8.
Release, 2008;127:131–6.
Banciu M, Metselaar JM, Schiffelers RM, Storm G, Liposomal glucocorticoids as tumor-targeted anti- angiogenic nanomedicine in B16 melanoma-bearing mice, J Steroid Biochem Mol Biol, 2008;111:101–10.
9.
Mulder WJ, Strijkers GJ, Habets JW, et al., MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle, FASEB J, 2005;19:2008–10.
10. Langereis S, Keupp J, van Velthoven JL, et al., A temperature-sensitive liposomal 1H CEST and 19F contrast agent for MR image-guided drug delivery, J Am Chem Soc, 2009;131:1380–82.
DRUG DISCOVERY
67
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84